The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration has granted breakthrough remedy designation to Enhertu (fam-trastuzumab deruxtecan-nxki) for grownup sufferers with HER2-positive early breast...
Actor Dave Coulier introduced in October that he had acquired an early-stage tongue-cancer prognosis often known as oropharyngeal squamous cell carcinoma, making...
